Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?

Crea, Francesco; Fornaro, Lorenzo; Masi, Gianluca; Falcone, Alfredo; Danesi, Romano; Farrar, William D.

doi:10.1200/jco.2011.37.0122

Cited by 14 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to distinguish between the CD133 protein and the AC133 epitope when discussing the expression of either in relation to CSCs. AC133 is generally considered to be the marker of CSCs [51][52][53] though it should be pointed out that there is the same heterogeneity in CSCs as seen in normal cancer cells [17]. While AC133 may be a marker of CSCs, not all CSCs express AC133.…”

Section: Discussionmentioning

confidence: 99%

RNA aptamers targeting cancer stem cell marker CD133

et al. 2013

View full text Add to dashboard Cite

The monoclonal antibody against the AC133 epitope of CD133 has been widely used as a cell surface marker of cancer stem cells in several different cancer types. Here, we describe the isolation and characterisation of two RNA aptamers, including the smallest described 15 nucleotide RNA aptamer, which specifically recognise the AC133 epitope and the CD133 protein with high sensitivity. As well, both these aptamers show superior tumour penetration and retention when compared to the AC133 antibody in a 3-D tumour sphere model. These novel CD133 aptamers will aid future development of cancer stem cell targeted therapeutics and molecular imaging.

show abstract

Section: Discussionmentioning

confidence: 99%

RNA aptamers targeting cancer stem cell marker CD133

et al. 2013

View full text Add to dashboard Cite

show abstract

“…More importantly, the oncofetal character of Lin28B may be advantageous over the other markers. For example, CD133 is expressed in the endothelial cells and thus is unreliable as a marker for circulating cancer stem cells [ 40 ]. Further survey will be needed to determine if adding Lin28B in a panel of cancer stem cell markers will increase the prognostic significance.…”

Section: Discussionmentioning

confidence: 99%

Lin28B Is an Oncofetal Circulating Cancer Stem Cell-Like Marker Associated with Recurrence of Hepatocellular Carcinoma

et al. 2013

View full text Add to dashboard Cite

By using an expressed sequence tag bioinformatic algorithm, we identified that Lin28 homolog B (Lin28B) may have an oncofetal expression pattern which may facilitate detecting cancer cells in adults. It is also reported to be a potential marker for cancer stem cells. Therefore, we sought to verify oncofetal-stemness characters of Lin28B and test its potential as a circulating cancer stem cell-like marker in adult HCC patients. Lin28B mRNA was examined in a panel of fetal tissue, adult tissue and tumors. Lin28B was over-expressed or knocked down in HepG2 cells to evaluate its potential as a stem cell-like marker. RT-qPCR for Lin28B was performed in the peripheral blood mononuclear cells from patients with HCC receiving surgery (n=96) and non-HCC controls (n=60) and analyzed its clinical significance. Lin28B showed an oncofetal expression pattern. Its overexpression could upregulate stemness markers (OCT4, Nanog and SOX2) and enhance tumorsphere formation in vitro. Lin28B knockdown had opposite effects. Circulating Lin28B was detected in peripheral blood mononuclear cells in 3 cases (5%) of non-HCC controls and 32 cases (33.3%) of HCC patients. In HCC patients, circulating Lin28B was associated with high tumor grade (P=0.046), large size (P=0.005), high AJCC stage (P=0.044) and BCLC stage (P=0.017). Circulating Lin28B was significantly associated with decreased recurrence-free survival (P<0.001). Circulating Lin28B separated early stage HCC into 2 recurrence-free survival curves (P=0.003). In multivariate analysis, circulating Lin28B was an independent variable associated with early recurrence (P=0.045) and recurrence in early stage HCC (P=0.006). In conclusion, the oncofetal gene Lin28B is a potential oncofetal cancer-stem-cell-like circulating tumor cell marker that correlates with HCC recurrence after hepatectomy. Circulating Lin28B could refine early AJCC stages. Our finding supports the possible use of a TNMC (C for circulating tumor cells) staging system in HCC.

show abstract

“…In a correlation study of CTC and CCSC from non-metastatic breast cancer patients, CTC was considered to be more appropriate for therapy assessment and CCSC as an independent prognostic marker for treatment failure and tumour recurrence [133]. Similar findings were reported for use of CD133 and CD44v9 CSC markers for predicting recurrence, prognosis, and treatment efficacy in colorectal cancer patient CTCs [134,135,136].…”

Section: Ctc Lines Ccsc Derived Csc Organoids For Future Tailoredmentioning

confidence: 86%

Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives

Perumal

Corica

Dharmarajan

et al. 2019

Cancers

View full text Add to dashboard Cite

Head and neck cancer is the seventh most common cancer in Australia and globally. Despite the current improved treatment modalities, there is still up to 50–60% local regional recurrence and or distant metastasis. High-resolution medical imaging technologies such as PET/CT and MRI do not currently detect the early spread of tumour cells, thus limiting the potential for effective minimal residual detection and early diagnosis. Circulating tumour cells (CTCs) are a rare subset of cells that escape from the primary tumour and enter into the bloodstream to form metastatic deposits or even re-establish themselves in the primary site of the cancer. These cells are more aggressive and accumulate gene alterations by somatic mutations that are the same or even greater than the primary tumour because of additional features acquired in the circulation. The potential application of CTC in clinical use is to acquire a liquid biopsy, by taking a reliable minimally invasive venous blood sample, for cell genotyping during radiotherapy treatment to monitor the decline in CTC detectability, and mutational changes in response to radiation resistance and radiation sensitivity. Currently, very little has been published on radiation therapy, CTC, and circulating cancer stem cells (CCSCs). The prognostic value of CTC in cancer management and personalised medicine for head and neck cancer radiotherapy patients requires a deeper understanding at the cellular level, along with other advanced technologies. With this goal, this review summarises the current research of head and neck cancer CTC, CCSC and the molecular targets for personalised radiotherapy response.

show abstract

Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?

Cited by 14 publications

References 13 publications

RNA aptamers targeting cancer stem cell marker CD133

RNA aptamers targeting cancer stem cell marker CD133

Lin28B Is an Oncofetal Circulating Cancer Stem Cell-Like Marker Associated with Recurrence of Hepatocellular Carcinoma

Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives

Contact Info

Product

Resources

About